NCT06731478 2026-03-16Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerDaiichi SankyoPhase 3 Recruiting726 enrolled
NCT04868877 2026-02-19Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationMerus B.V.Phase 1/2 Active not recruiting194 enrolled